Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LOC100507053 (ENSG00000246090) is classified as a long non-coding RNA (lncRNA) that acts as a natural antisense transcript to the genes alcohol dehydrogenase 4 (ADH4), alcohol dehydrogenase 6 (ADH6), and alcohol dehydrogenase 1A (ADH1A). Its specific molecular function remains uncharacterized, but as an antisense transcript, it is hypothesized to function as a local regulator of gene expression, potentially modulating the expression of genes involved in processes such as secretion, metabolism, fibroblast activation, and the maintenance of tissue barriers[1][3][5]. There is no evidence to suggest it functions directly as a receptor, enzyme, or classical therapeutic target. Its role is currently understood to be in RNA-based regulation rather than as a protein-coding gene. It is not commonly referenced as a disease biomarker, pharmacological target, or safety concern.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript antisense to alcohol dehydrogenase 4, alcohol dehydrogenase 6, and alcohol dehydrogenase 1A (LOC100507053 (also ENSG00000246090)).